Reimbursement of the novel domestic drug ‘Leclaza’ that was due today (July 1st) was postponed.

The listing process of Yuhan Corporation’s new drug which had been progressing at an unprecedented pace came to a full stop due to ‘companion diagnostics.’

Dailypharm found that the Ministry of Health and Welfare had pulled a temporary stop on the enforcement of the notice related to Leclaza (lazertinib). Leclaza was supposed to be listed from July after passing the Health Insurance Policy Deliberative Committee’s review on the 25th of last month.

The brakes were pulled by an objection that was registered during the pre-announcement of administration period regarding the l